In an in vitro model, this is associated with increased activation of NK cells and decreased tumour cell viability in the presence of PBMCs, thus providing the rationale for a clinical trial which combines NUC-3373 with anti-PD1 (NCT05714553). Here, PDCD1 is linked to neoplasm.